|1.||Monneret, Guillaume: 14 articles (01/2014 - 07/2003)|
|2.||Venet, Fabienne: 13 articles (01/2014 - 07/2003)|
|3.||Meisel, Christian: 11 articles (01/2015 - 05/2003)|
|4.||Kirkwood, John M: 9 articles (01/2014 - 01/2002)|
|5.||Goldenberg, David M: 8 articles (01/2013 - 01/2005)|
|6.||Lepape, Alain: 8 articles (01/2013 - 07/2003)|
|7.||Volk, Hans-Dieter: 8 articles (01/2013 - 05/2003)|
|8.||Baudouin, Christophe: 8 articles (11/2011 - 01/2002)|
|9.||David, Chella S: 8 articles (08/2011 - 04/2002)|
|10.||Granados, Julio: 8 articles (12/2010 - 03/2002)|
01/01/2007 - "bcl-2 and HLA-DR protein expressions of the tumor infiltrate were statistically significant independent prognostic factors suggesting improved survival (p = 0.0272 and p = 0.0285, respectively). "
04/01/1998 - "HLA-DR antibody stained the stroma and cellular infiltrates surrounding the primary tumor in 28 of 40 patients; in this group there was a correlation of HLA-DR staining of the peritumoral stroma with improved survival overall. "
01/01/2014 - "The change in Treg observed within the tumor showed an inverse relationship with clinical benefit and greater decrease in tumor MDSC subset Lin1-/HLA-DR-/CD33⁺/CD11b⁺ was associated with improved PFS at one year. "
01/01/2014 - "Our studies identified a deficiency in the ability to generate mature dendritic cell using CD14(+) cells from cancer patients that corresponded with an increased population of monocytes with altered surface marker expression (CD14(+)HLA-DR(lo/neg)). "
04/01/2013 - "Given the relation between cancer incidence and age, this study examined the frequency of peripheral blood CD33(+)HLA-DR(-) MDSCs across three cohorts: healthy adults (19-59 years old), community-dwelling seniors (61-76 years old), and frail elderly (67-99 years old). "
03/01/2015 - "This study was performed to investigate the association between the HLA-DR series and rheumatoid arthritis (RA) in a Thai population. "
05/01/2014 - "In the present study, our aim was to investigate the distribution of HLA-DR/DQ alleles among Kurd patients with rheumatoid arthritis and to ascertain their relationship with disease activity. "
01/01/2000 - "We generated HLA-DR and DQ transgenic mice that lacked endogenous class II molecules to study the interaction between the DR and DQ molecules and define the immunologic mechanisms in rheumatoid arthritis. "
06/01/1995 - "Extensive studies in different ethnic groups have associated the susceptibility to development of rheumatoid arthritis (RA) with the third hypervariable region of the major histocompatibility complex (MHC) HLA-DR beta 1 molecule. "
08/01/1993 - "This study used the polymerase chain reaction to amplify HLA-DR beta and DQ beta genes, and oligonucleotide probe hybridisation to examine the association of certain polymorphic sequences with rheumatoid arthritis in 23 Chinese patients from Shanghai. "
06/01/2002 - "Surface-marker analysis of the leukemia cells showed positive results for CD11b, CD11c, CD13, CD15, CD33, CD56, CD64, CD65, CD71 and HLA-DR, and chromosomal analysis revealed add(8) (p11), add(9) (p13). "
05/01/2010 - "The patient's bone marrow aspiration and biopsy suggested AML, and the leukemia panel 1 study showed CD13, CD33, CD34, and HLA DR-positive AML with CD7 expression. "
09/01/2009 - "The results of the present study show that an immunophenotypic, molecular, and cytomorphologic separation of both HLA-DR(neg) leukemia subgroups is possible indicating that both groups are biologically distinct."
04/01/2003 - "A surface marker study revealed the presence of a single clone that was positive for CD7, CD33, CD34, and HLA-DR. A diagnosis of hypoplastic leukemia was made on the basis of morphology and the surface marker studies. "
08/01/2015 - "However, these levels did not correlate with percentage or median fluorescence intensity of HLA-DR expressed on leukemia blasts (CD19+CD34 ± CD45(lo)HLA-DR+) or in the normal B cell population (CD19+CD34- CD45(hi)HLA-DR+) of patients. "
12/01/1990 - "HLA-DR expression in B-cell non-Hodgkin's malignant lymphomas: a multiparameter flow cytometry study."
11/01/2015 - "A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR."
01/01/2015 - "However, the underlying mechanism by which CD14(+)HLA-DR(low/-) monocytes develop in lymphoma is unknown. "
12/01/2014 - "HLA-DR expression by lymphoma cells was evaluated using flow cytometry, and TAMs in lymphoma tissue were detected by immunohistochemistry for CD68 as a marker of macrophages and CD163 as a marker of M2 TAMs. "
05/01/2014 - "Our data indicated that combined targeting of CD20 and HLA-DR could be an effective approach against malignancies, suggesting that CD20-243 CrossMab would be a promising therapeutic agent against lymphoma. "
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
09/01/2009 - "The purpose of this study was to investigate whether further biological characterization of the HLA-DR(neg) acute myeloid leukemia patients would allow more clearly define criteria to separate APL from non-APL patients. "
01/01/2015 - "Conversion from nuclear bilobation to indentation in BCR/ABL1-positive acute myeloid leukemia lacking CD34 and HLA-DR expression."
10/01/2014 - "Flow cytometry was performed on 29 newly diagnosed APLs and 93 other acute myeloid leukemias, including 25 HLA-DR- or CD34- cases. "
06/01/2014 - "Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome."
01/01/2011 - "Blasts in acute myeloid leukemias (AML) with minimal differentiation have low SSC and moderate CD45 expression and are positive for CD34, CD117, CD13, HLA-DR, and CD33 and may be positive for TdT, CD4, and CD11c. "
|4.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|6.||Interleukin-2 Receptors (IL 2 Receptor)
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|1.||Drug Therapy (Chemotherapy)
|5.||Surgical Instruments (Clip)